ArticlePharmacological research2025

Pyrazolone-based ERO1 inhibitors in ERO1-driven triple-negative breast cancer and SEPN1-related myopathy: Structure-activity relationship and therapeutic potential.

Michele Retini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.